Publications by authors named "E V Navolotskaia"

Peptide CH3CO-Lys-Lys-Arg-Arg-NH2 (protectin) was synthesized and its activity was studied on the model of experimental myocardial infarction in rats in comparison to the reference antihypoxant drug riboxin. Intranasal injections ofprotectin at doses within 2-20 microg/kg once a day by course of 7 days produced a pronounced anti-ischemic action, improved coronary circulation of the blood, increases contractile activity of myocardium, reduced intensity of lipid peroxidation, and improved antioxidant protection. In some respects (improved coronary circulation of the blood, increased antioxidant protection), protectin was more effective than riboxin.

View Article and Find Full Text PDF

We have synthesized the peptide TPLVTLFK corresponding to the β-endorphin fragment 12-19 (the name given by the authors - octarphin), and its analogs (LPLVTLFK, TLLVTLFK, TPLVLLFK, TPLVTLLK, TPLVTLFL). The peptide octarphin was labeled with tritium (the specific activity of 28 Ci/mmol) and its binding to the murine peritoneal macrophages has been studied. [(3)H]Octarphin was found to bind to macrophages with high affinity (K(d) = 2.

View Article and Find Full Text PDF

Research results of the synthetic decapeptide SLTCLVKGFY (the author's term is immunorphin) corresponding to the 364-373 sequence of G heavy-chain human immunoglobulin are summarized. Special attention is paid to the interaction between immunorphin and a nonopioid (insensitive to the opioid antagonist naloxone) beta-endorphin receptor. Using radioligand analysis, data were found regarding the distribution and functions of a nonopioid beta-endorphin receptor in human and animal bodies and the binding characteristics of immunorphin with a nonopioid receptor.

View Article and Find Full Text PDF

The CH3CO-Lys-Lys-Arg-Arg-NH2 peptide (the author has named it protectin) was synthesized, and its activity was studied during different stress actions. Protectin was found to normalize the content of corticosterone and adrenalin in adrenal glands and blood after its intranasal administration to rats one day before a cold or heat shock, or hypobaric hypoxia at doses of 1-10 microg/animal and after its intravenous administration just after acute hemorrhage at doses of 0.5-2 microg/animal.

View Article and Find Full Text PDF

The activity of the KKRR synthetic peptide corresponding to the 15-18 sequence of human adrenocorticotropic hormone (ACTH) and its analogues KKKK, RRRR, RRKK, kKRR, KkRR, KKrR, and KKRr (amino acid residues of the D configuration are designated by small letters) was studied in vivo on rats under cold and heat shock. Intranasal administration of the KKRR peptide at doses of 2-10 microg/animal 1 day before the shock was found to prevent a dramatic increase in the level of corticosterone in rat adrenal glands and blood plasma caused by the temperature effect. Amino acid substitutions in the KKRR peptide were shown to result in an abrupt decrease in its activity.

View Article and Find Full Text PDF